Noven has studied the feasibility of transdermal delivery of drugs in a broad range of therapeutic categories. The following list represents compounds that we view as promising candidates for transdermal delivery based on internal assessments. Many of these compounds are available for collaborative development. Several are under patent protection by third parties and are presented to illustrate that they may be delivered transdermally using our patented technology.

Noven's Transdermal Drug Development Portfolio of Opportunities


ADHD
Amphetamine

Alzheimer's
Tacrine

Angina
Nitroglycerine
Isosorbide Dinitrate

Anxiety
Alprazolam

Birth Control
Estrogen/Progestin/
Combinations

Depression
Buspirone
Bupropion

Epilepsy
Clonazepam

Hypertension
Enalapril
Ramipril
Clonidine
Timolol
Guanfacine

Hypogonadism/
FSD
Testosterone

Motion Sickness
Scopolomine

Muscle Spasms
Cyclobenzaprine

Nausea
Granisetron

Obesity
Phentermine
Methamphetamine

Pain
Buprenorphine
Sufentanil
Levorphanol
Lidocaine
Various NSAIDs
Various Triptans

Parkinson's
Pergolide
Pramipexole
Ropinirole
Rotigotine

Urinary Incontinence
Tolterodine
Oxybutynin


If you are interested in discussing the feasibility of transdermal delivery for one of your compounds, or licensing one of Noven’s development products in the U.S. or abroad, please contact Patrick Gallagher, Vice President – Business Development.

 

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.